

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM475587

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
BSP Agency, LLC, as Successor Agent		05/25/2018	Limited Liability Company: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Evolution Research Group, LLC		
<b>Street Address:</b>	12 New Providence Road		
<b>City:</b>	Watchung		
<b>State/Country:</b>	NEW JERSEY		
<b>Postal Code:</b>	07069		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 7</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4949830	MIDWEST CLINICAL RESEARCH	
<b>Registration Number:</b>	4935890	PRN PACIFIC RESEARCH NETWORK	
<b>Registration Number:</b>	4801201	ERG	
<b>Registration Number:</b>	4768321	WOODLAND INTERNATIONAL RESEARCH GROUP	
<b>Registration Number:</b>	4768237	ST. LOUIS CLINICAL TRIALS	
<b>Registration Number:</b>	4768231	THIEVON-WRIGHT CONSULTING GROUP	
<b>Serial Number:</b>	87215116	CPMI CLINICAL PHARMACOLOGY OF MIAMI WHER	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2123548113		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2128198200		
<b>Email:</b>	iprecordations@whitecase.com		
<b>Correspondent Name:</b>	Matthew Campion/White & Case LLP		
<b>Address Line 1:</b>	1221 Avenue of the Americas		
<b>Address Line 2:</b>	Patent and Trademark Dept.		
<b>Address Line 4:</b>	New York, NEW YORK 10020		
<b>NAME OF SUBMITTER:</b>	Matthew Campion		
<b>SIGNATURE:</b>	/Matthew Campion/		

CH \$190.00 4949830

<b>DATE SIGNED:</b>	05/25/2018
<b>Total Attachments: 3</b> source=ERG - Evolution Research Release#page1.tif source=ERG - Evolution Research Release#page2.tif source=ERG - Evolution Research Release#page3.tif	

**TERMINATION AND RELEASE OF SECURITY INTEREST  
IN INTELLECTUAL PROPERTY**

This **TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY**, dated as of May 25, 2018 (“Release”), is made by BSP Agency, LLC, as Successor Agent (“Successor Agent”) in favor of Evolution Research Group, LLC, a Delaware limited liability company (“Grantor”).

**WHEREAS**, pursuant to that certain Amended and Restated Security and Pledge Agreement dated as of July 31, 2017 (as amended, restated, supplemented, modified, extended, renewed or replaced from time to time, the “Security Agreement”) by and among the Grantor, Business Development Corporation of America, as Administrative Agent (“Prior Agent”), and others party thereto, Grantor granted to the Prior Agent, for the ratable benefit of the Lenders, a continuing security interest in Grantor’s right, title and interest of Grantor in and to all Copyrights, Copyright Licenses, Patents, Patent Licenses, Trademarks, Trademark Licenses, and Proceeds of the foregoing (collectively, “IP Collateral”);

**WHEREAS**, pursuant to the Security Agreement, Grantor executed and delivered to the Prior Agent, for the benefit of the Lenders, the Notice of Grant of Security Interest in Intellectual Property recorded at the United States Patent and Trademark Office (“USPTO”) on August 1, 2017 at Reel 6120 Frame 0966 (“IP Notice”);

**WHEREAS**, pursuant to the Successor Agent Agreement dated as of March 1, 2018 (“Successor Agent Agreement”), by and among the Prior Agent, the Successor Agent, and others party thereto, the Prior Agent was replaced by the Successor Agent under the Security Agreement and IP Notice, and the security interests granted thereunder by Grantor were transferred to the Successor Agent; and

**WHEREAS**, pursuant to the Successor Agent Agreement, Prior Agent and Successor Agent entered into the Notice of Succession of Agency (Intellectual Property) dated as of March 1, 2018 and submitted for recordation at the USPTO on or about May 10, 2018 (“Succession Notice”).

**NOW THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Successor Agent, on behalf of the Lenders, and Grantor agree as follows:

**SECTION 1. Defined Terms.** All capitalized terms used herein but not otherwise defined herein have the meanings given to them in the Security Agreement, IP Notice, or Succession Notice.

**SECTION 2. Termination and Release.** Successor Agent, on behalf of the Lenders, without representation, warranty, or recourse, hereby:

(a) terminates, cancels, discharges, and releases the continuing security interest in Grantor’s right, title, and interest in and to the IP Collateral, including, but not limited to, the foregoing listed on Schedule A attached hereto, granted pursuant to the Security Agreement, IP Notice, or Succession Notice; and


(b) authorizes the recordation of this Release with the USPTO at Grantor’s expense.

**SECTION 3. Choice of Law.** This Release shall be governed by and construed in accordance with the laws of the State of New York.

IN WITNESS WHEREOF, the Successor Agent, on behalf of the Lenders, has caused this Termination and Release of Security Interest in Intellectual Property to be duly executed as of the date first set forth above.

Successor Agent:

BSP Agency, LLC ~~Successor Agent~~

By: 

Name: Bryan Martoken

Title: Authorized Signer

**Schedule A**

**Evolution Research Group, LLC  
(Delaware Limited Liability Company)**

**U.S. Trademarks Subject to Security Interest  
Granted by Evolution Research Group, LLC  
In Favor of Business Development Corporation of America, as Administrative Agent  
Recorded August 1, 2017 at Reel 6120 Frame 0966  
Security Interest Assigned in Favor of BSP Agency, LLC, as Successor Agent  
Security Interest Assignment Submitted for Recordation on or about May 10, 2018**

**Trademark Registrations**

<b>Mark</b>	<b>Reg. No.</b>	<b>Reg. Date</b>
MIDWEST CLINICAL RESEARCH and Design	4949830	05/03/16
PRN PACIFIC RESEARCH NETWORK and Design	4935890	04/12/16
ERG and Design	4801201	08/25/15
WOODLAND INTERNATIONAL RESEARCH GROUP and Design	4768321	07/07/15
ST. LOUIS CLINICAL TRIALS and Design	4768237	07/07/15
THIEVON-WRIGHT CONSULTING GROUP and Design	4768231	07/07/15

**Trademark Application**

<b>Mark</b>	<b>Appl. No.</b>	<b>Filing Date</b>
CPMI CLINICAL PHARMACOLOGY OF MIAMI WHERE EXPERIENCE AND EXCELLENCE MEET and Design	87215116	10/25/16